Using genetic editing and cell therapy to treat osteopetrosis caused by CLCN7 mutations
Genetic editing and cell therapy for correction of CLCN7 mutations in osteopetrosis
This study is exploring new ways to help people with osteopetrosis by using genetic editing to fix a specific gene, aiming to improve bone health and reduce complications without the risks of current treatments like bone marrow transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10849327 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for osteopetrosis, a genetic disorder that leads to excessive bone density and various complications. The approach involves genetic editing to correct mutations in the CLCN7 gene, which is crucial for the function of bone-resorbing cells called osteoclasts. By utilizing cell therapy, the research aims to restore normal bone remodeling and improve patient outcomes. The study seeks to address the limitations of current treatments, such as bone marrow transplantation, which can have significant risks and complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with osteopetrosis due to CLCN7 mutations, particularly those who are not eligible for traditional bone marrow transplantation.
Not a fit: Patients with osteopetrosis caused by mutations in genes other than CLCN7 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with osteopetrosis, potentially improving their quality of life and reducing complications.
How similar studies have performed: While there have been some promising approaches using gene therapy for similar conditions, this specific method of genetic editing and cell therapy for CLCN7 mutations in osteopetrosis is relatively novel and has not been extensively tested.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Jacome-Galarza, Christian E — Brigham and Women's Hospital
- Study coordinator: Jacome-Galarza, Christian E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.